Limits...
Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.

Staskin DR, Rosenberg MT, Dahl NV, Polishuk PV, Zinner NR - Int. J. Clin. Pract. (2007)

Bottom Line: Mean KHQ scores decreased significantly (p<or=0.0196) from baseline to study end in eight of 10 domains, indicating improved health-related quality of life.The proportion of men with BDI-II score>12 (associated with a diagnosis of depression) decreased from 23.9% to 17.9% (p=0.0055).Most men (76.2%) reported no treatment-related adverse events; two men (0.5%) experienced symptoms of mild urinary retention, but neither required catheterisation.

View Article: PubMed Central - PubMed

Affiliation: Weill Medical College of Cornell University, New York, NY 10021, USA. das2021@med.cornell.edu

ABSTRACT

Aims: Overactive bladder (OAB) is common in men and may exist concomitantly with benign prostatic hyperplasia (BPH) and obstruction. We present a subanalysis of results from men with OAB in a 6-month, open-label study of treatment with the oxybutynin transdermal system (OXY-TDS). Broad entry criteria were incorporated to yield a clinically representative population.

Methods: All participants received OXY-TDS 3.9 mg/day. Effectiveness was assessed by changes in scores on validated questionnaires, which included the single-item Patient Perception of Bladder Condition (PPBC), the King's Health Questionnaire (KHQ) and the Beck Depression Inventory-II (BDI-II).

Results: The proportion of men (n=369; mean age=69.6 years) who reported that their bladder condition caused moderate, severe or many severe problems (PPBC>or=4) improved from 77.3% at baseline to 38.1-53.6% in subsequent months. Mean KHQ scores decreased significantly (p12 (associated with a diagnosis of depression) decreased from 23.9% to 17.9% (p=0.0055). Men with a history of 'prostate problems' or use of 'BPH medication' (32.2%) had KHQ domain changes that were similar (p>or=0.1016) to those of other men. Most men (76.2%) reported no treatment-related adverse events; two men (0.5%) experienced symptoms of mild urinary retention, but neither required catheterisation.

Conclusions: Oxybutynin transdermal system treatment of men with OAB was effective and well tolerated, regardless of history of prostate condition.

Show MeSH

Related in: MedlinePlus

Improvement in health-related quality of life (HRQoL) in men with and without pre-existing prostate problems, assessed as mean changes in King's Health Questionnaire (KHQ) domain scores from baseline to study end. All changes in score were similar between the two groups (p ≥ 0.1016); analysis of co-variance (ANCOVA)
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2228367&req=5

fig04: Improvement in health-related quality of life (HRQoL) in men with and without pre-existing prostate problems, assessed as mean changes in King's Health Questionnaire (KHQ) domain scores from baseline to study end. All changes in score were similar between the two groups (p ≥ 0.1016); analysis of co-variance (ANCOVA)

Mentions: Men with and without pre-existing prostate problems had similar (p ≥ 0.1575; ANCOVA) baseline scores in all 10 KHQ domains. HRQoL improved in both groups from baseline to study end, as was shown by mean decreases in nine of 10 KHQ domain scores (Figure 4); changes were similar (p ≥ 0.1016; ANCOVA) in all 10 domains for both groups.


Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.

Staskin DR, Rosenberg MT, Dahl NV, Polishuk PV, Zinner NR - Int. J. Clin. Pract. (2007)

Improvement in health-related quality of life (HRQoL) in men with and without pre-existing prostate problems, assessed as mean changes in King's Health Questionnaire (KHQ) domain scores from baseline to study end. All changes in score were similar between the two groups (p ≥ 0.1016); analysis of co-variance (ANCOVA)
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2228367&req=5

fig04: Improvement in health-related quality of life (HRQoL) in men with and without pre-existing prostate problems, assessed as mean changes in King's Health Questionnaire (KHQ) domain scores from baseline to study end. All changes in score were similar between the two groups (p ≥ 0.1016); analysis of co-variance (ANCOVA)
Mentions: Men with and without pre-existing prostate problems had similar (p ≥ 0.1575; ANCOVA) baseline scores in all 10 KHQ domains. HRQoL improved in both groups from baseline to study end, as was shown by mean decreases in nine of 10 KHQ domain scores (Figure 4); changes were similar (p ≥ 0.1016; ANCOVA) in all 10 domains for both groups.

Bottom Line: Mean KHQ scores decreased significantly (p<or=0.0196) from baseline to study end in eight of 10 domains, indicating improved health-related quality of life.The proportion of men with BDI-II score>12 (associated with a diagnosis of depression) decreased from 23.9% to 17.9% (p=0.0055).Most men (76.2%) reported no treatment-related adverse events; two men (0.5%) experienced symptoms of mild urinary retention, but neither required catheterisation.

View Article: PubMed Central - PubMed

Affiliation: Weill Medical College of Cornell University, New York, NY 10021, USA. das2021@med.cornell.edu

ABSTRACT

Aims: Overactive bladder (OAB) is common in men and may exist concomitantly with benign prostatic hyperplasia (BPH) and obstruction. We present a subanalysis of results from men with OAB in a 6-month, open-label study of treatment with the oxybutynin transdermal system (OXY-TDS). Broad entry criteria were incorporated to yield a clinically representative population.

Methods: All participants received OXY-TDS 3.9 mg/day. Effectiveness was assessed by changes in scores on validated questionnaires, which included the single-item Patient Perception of Bladder Condition (PPBC), the King's Health Questionnaire (KHQ) and the Beck Depression Inventory-II (BDI-II).

Results: The proportion of men (n=369; mean age=69.6 years) who reported that their bladder condition caused moderate, severe or many severe problems (PPBC>or=4) improved from 77.3% at baseline to 38.1-53.6% in subsequent months. Mean KHQ scores decreased significantly (p12 (associated with a diagnosis of depression) decreased from 23.9% to 17.9% (p=0.0055). Men with a history of 'prostate problems' or use of 'BPH medication' (32.2%) had KHQ domain changes that were similar (p>or=0.1016) to those of other men. Most men (76.2%) reported no treatment-related adverse events; two men (0.5%) experienced symptoms of mild urinary retention, but neither required catheterisation.

Conclusions: Oxybutynin transdermal system treatment of men with OAB was effective and well tolerated, regardless of history of prostate condition.

Show MeSH
Related in: MedlinePlus